Sobre la sociedad
Skye Bioscience, Inc., a clinical-stage biotechnology company, develops molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related metabolic diseases. The company's lead clinical asset is nimacimab, a peripherally-restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1) administered as a subcutaneous injectable, which targets CB1 receptors in peripheral tissues including adipose, liver, and muscle tissues with limited central nervous system accumulation. Nimacimab addresses metabolic processes related to energy expenditure, fat mobilization, leptin sensitivity, appetite regulation, and satiety signaling. Skye Bioscience, Inc. was formerly known as Emerald Bioscience Inc. and changed its name to Skye Bioscience, Inc. in December 2020. Skye Bioscience, Inc. was incorporated in 2011 and is based in San Diego, California.
- Sector
- Healthcare
- Actividad
- Biotechnology
- Mercado de cotización
- NASDAQ
Cotización registradaEstado del valor según la última fuente recibida, no una garantía de negociabilidad.
Fuente de información de mercado · Oct 19, 2026
Nombres anteriores
Periodos registrados en las fuentes consultadas. No certifican las fechas legales de los cambios de nombre.
- Emerald Bioscience, Inc.Mar 25, 2019 / Jan 7, 2021
- Nemus Bioscience, Inc.Nov 3, 2014 / Mar 14, 2019
- LOAD GUARD LOGISTICS, INC.Nov 8, 2012 / Oct 30, 2014
- LOAD GUARD TRANSPORTATION, INC.Mar 25, 2011 / Nov 7, 2012
Identidad según la SEC · Oct 19, 2026